6. ClearPoint Neuro Inc. (NASDAQ:CLPT)
ClearPoint Neuro, Inc. (NASDAQ: CLPT) takes the No. 6 position as a picks-and-shovels investment in minimally invasive neurosurgery and neurological gene therapy. The company provides navigation platforms, cannulas, planning software, and procedural support that help physicians deliver treatments accurately to targeted areas inside the brain.
Second-quarter 2026 revenue increased 18% to approximately $10.9 million, supported by neurosurgery navigation, therapy products, capital equipment, and the acquired IRRAflow portfolio. Biologics and Drug Delivery revenue declined 15% because fewer products were shipped to biopharmaceutical customers supporting new clinical-trial initiations. The company also recorded a quarterly net loss of approximately $11.3 million.
ClearPoint Neuro, Inc. (NASDAQ: CLPT) could benefit if partner-sponsored neurological therapies successfully move through clinical development and reach commercialization, creating recurring demand for its delivery technology. However, partner dependency, continued cash consumption, debt, unpredictable trial schedules, and widening losses keep the stock in the speculative category.
YOU MUST READ THIS: Top 10 Healthcare Stocks to Buy With $1000 in 2026
Click here to continue reading and checkout the Top 5 Small-Cap Medical Stocks to Buy Before August 2026 Ends
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
